Tevogen (TVGN) Research & Development (2023 - 2026)

Tevogen (TVGN) has reported Research & Development for 4 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 1.89% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $11.1 million (down 17.63% YoY), and the FY2025 full-year result was $11.1 million, down 64.19% from the prior year.
• Research & Development improved to $3.1 million in Q1 2026 per TVGN's latest filing, from $2.1 million in the prior quarter.
• Across five years, Research & Development topped out at $20.8 million in Q1 2024 and bottomed at $908049.0 in Q4 2023.
• Historically, Research & Development has averaged $3.8 million across 4 years, with a median of $2.8 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Research & Development jumped 1444.83% in 2024, then tumbled 84.65% in 2025.
• Over 4 years, Research & Development stood at $908049.0 in 2023, then jumped by 212.35% to $2.8 million in 2024, then slipped by 25.76% to $2.1 million in 2025, then soared by 48.87% to $3.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $3.1 million, $2.1 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.